|
|
|
Edwards Lifesciences Corporation (NYSE: EW) |
|
|
|
| |
Edwards Lifesciences Corporation Outlook |
On April 26 2024 the Edwards Lifesciences Corporation provided following guidance
Edwards Lifesciences Corporation (NYSE: EW) announced its financial results for the first quarter of 2024, reporting strong growth in sales and earnings. The company posted a 10% increase in sales on a reported basis, reaching $1.6 billion for the quarter. Sales also grew by 10% on a constant currency basis, indicating solid performance across markets.
Specifically, sales of transcatheter aortic valve replacement (TAVR) products increased by 6% in the first quarter, with constant currency sales up by 8% when adjusted for billing days. Sales in the transcatheter mitral and tricuspid therapies (TMTT) segment experienced significant growth of 75%, reflecting the company's continued focus on innovation and expanding its product portfolio.
Earnings per share (EPS) for the first quarter were reported at $0.58, with adjusted EPS standing at $0.66. This performance demonstrates the company's ability to deliver strong financial results while investing in research and development to drive future growth.
Looking ahead, Edwards Lifesciences raised its sales guidance for 2024 to the high end of the previous 8 to 10% range, indicating confidence in its ability to sustain growth momentum throughout the year. Additionally, the company increased its full-year sales guidance for the TMTT segment, highlighting the potential for continued expansion and market leadership in this key growth area.
Overall, Edwards Lifesciences Corporation's strong first-quarter results and increased sales guidance for 2024 reflect the company's ongoing commitment to innovation, market leadership, and delivering value to patients and shareholders alike.
|
On February 6 2024 the Edwards Lifesciences Corporation provided following guidance
the company's TAVR technology in patients with low-risk aortic stenosis Announced plans to acquire an advanced surgical valve technology company, expanding the company's product portfolio Completed enrollment in a clinical trial for the company's SAPIEN 3 Ultra valve Continues to focus on innovation and expanding access to its life-saving therapies Expects 2024 sales to be in the range of $7.0 billion to $7.3 billion Expects adjusted EPS for 2024 to be in the range of $3.00 to $3.20 The company's strong financial performance in 2023 and positive outlook for 2024 reflect the continued demand for its innovative medical devices and therapies. Edwards Lifesciences is committed to improving patient outcomes and delivering value to its shareholders.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
